Therapeutic targeting in breast cancer for the treatment of lymph node metastasis: PTPN4.

Fuente: Zenodo
Guardado en:
Detalles Bibliográficos
Autor principal: Mamoor, Shahan
Formato: Recurso digital
Publicado: Zenodo 2025
Acceso en línea:
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
_version_ 1866902245987057664
author Mamoor, Shahan
author_facet Mamoor, Shahan
contents <p dir="ltr">Metastasis is the major cause of death from cancer (1); metastasis to the lymph nodes in breast cancer is dangerous, relatively common, and in one study ranged from 10-60% based on molecular subtype (2-4).  We predict therapeutic index is intrinsically linked to differential expression which can be comprehensively and blindly determined using whole transcriptome data (5).  We pioneered understanding of metastasis to the lymph nodes as an intermediate biological and anatomical counterpart to the CNS metastasis in humans (6-12).  Here we utilize whole transcriptome technologies (13, 14) to measure total transcription in the lymph node metastases and primary tumors of humans with breast cancer for discovery and insight into clonal evolution through disease progression.  We identify here a therapeutic target based on its differential expression and up-regulation upon metastasis to the lymph nodes in humans with breast cancer, PTPN4, as a candidate therapeutic target for the medical management of lymph node metastasis.    </p>
format Recurso digital
id zenodo_https___doi_org_10_5281_zenodo_15175952
institution Zenodo
language
publishDate 2025
publisher Zenodo
record_format zenodo
spellingShingle Therapeutic targeting in breast cancer for the treatment of lymph node metastasis: PTPN4.
Mamoor, Shahan
<p dir="ltr">Metastasis is the major cause of death from cancer (1); metastasis to the lymph nodes in breast cancer is dangerous, relatively common, and in one study ranged from 10-60% based on molecular subtype (2-4).  We predict therapeutic index is intrinsically linked to differential expression which can be comprehensively and blindly determined using whole transcriptome data (5).  We pioneered understanding of metastasis to the lymph nodes as an intermediate biological and anatomical counterpart to the CNS metastasis in humans (6-12).  Here we utilize whole transcriptome technologies (13, 14) to measure total transcription in the lymph node metastases and primary tumors of humans with breast cancer for discovery and insight into clonal evolution through disease progression.  We identify here a therapeutic target based on its differential expression and up-regulation upon metastasis to the lymph nodes in humans with breast cancer, PTPN4, as a candidate therapeutic target for the medical management of lymph node metastasis.    </p>
title Therapeutic targeting in breast cancer for the treatment of lymph node metastasis: PTPN4.
url https://doi.org/10.5281/zenodo.15175952